The FDA endorsement for Phase 3 initiation of sutacimig in GT is the most significant catalyst — watch for trial enrollment updates and data readouts in late 2026/early 2027. HMB-002 and HMB-003 data readouts in late 2026/early 2027 are secondary catalysts. The strong cash runway removes near-term financing risk.
Price Chart
Executive Summary
Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line with consensus of $-0.82. The company highlighted FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, positive Phase 1/2 data for HMB-002 in Von Willebrand Disease, and unveiled a new preclinical program HMB-003. Cash position strengthened to $457.5M post-IPO, providing runway into 2029. The stock will move on pipeline catalysts rather than the pre-revenue financials.
Key Financial Metrics
Key Facts
- Net loss of $24.2M ($0.80/share) vs consensus $-0.82 — in line
- Cash, cash equivalents, and marketable securities totaled $457.5M as of June 30, 2026, up from $163.5M at March 31, 2026
- FDA endorsed clinical data package for sutacimig as sufficient to proceed to Phase 3 pivotal trial in Glanzmann thrombasthenia; Phase 3 initiation planned 2H 2026
- HMB-002 Phase 1/2 data showed 2.4-fold increase in VWF and FVIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days
- Unveiled HMB-003, a novel peptide-based plasmin inhibitor for heavy menstrual bleeding; first-in-human studies planned 2H 2026
- R&D expenses $20.3M (Q2 2026) vs $12.9M (Q2 2025), reflecting clinical program advancement
Financial Impact
Q2 2026 net loss of $24.2M ($0.80/share) vs consensus $-0.82 — in line. Cash runway extended into 2029 with $457.5M post-IPO.
Risk Factors
- Phase 3 trial failure or safety signal in sutacimig
- Competition from existing therapies (recombinant Factor VIIa, platelet transfusions)
- Dilution risk if additional capital is needed beyond current runway
- Clinical trial enrollment delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343421 |
| Document: d180684d8k.htm | 0001193125-26-343421 |
| Document: 0001193125-26-343421-index-headers.html | 0001193125-26-343421 |
| Document: 0001193125-26-343421-index.html | 0001193125-26-343421 |
| Document: 0001193125-26-343421.txt | 0001193125-26-343421 |
| 8-K Data (Synthetic) | 0001193125-26-343421 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access